Tetraphase Pharmaceuticals (TTPH) PT Lowered to $6 at Stifel; Path Forward Complicated, But Still There
Tweet Send to a Friend
Stifel lowered its price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $6.00 (from $13.00) while maintaining a Buy rating following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
